J. Turgeon, B. Pharm., Ph.D.
Publications 2013-2019

CURRICULUM VITAE

Chief Scientific Officer
Tabula Rasa HealthCare (TRHC)
Chief Executive Officer
TRHC (Scientific Precision Pharmacotherapy Research & Development Institute
13485 Veteran’s Way, Suite 400
Orlando, Florida, 32827
Phone: 856-938-8793

Jacques Turgeon, B.Pharm., Ph.D.
jturgeon@trhc.com


A) Original Manuscripts:


B) Abstracts:


331. Lu, J., Guilarte Moya, L.G., Leung, Y., Gaudette, F., Turgeon, J. Tricyclic compounds inhibit the OATP1A2 transporter, CSPT 2013, Boston, MA.


333. Leung, Y., Lu, J., Papillon, M., Bélanger, F., Turgeon, J., Michaud, V. The role of MCT1 and MCT4 in drug-induced muscle disorders, CSPT 2013, Boston, MA.


354. Gravel, S., Grangeon, A., Gaudette, F., Chiasson, J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaud, V. Type 2 diabetes modulates CYP450 metabolic activities. 10th MDRC annual meeting. Montreal, Quebec, 2016. Oral poster (ranked in the top 10%)


361. Steffen, L.E., Badea, G., Cicali, B., Knowlton, C.H., Turgeon J. Medication-Specific Long QT-JT Index And Patient-Specific Long QT-JT Score For Assessing Risk Of Torsade De Pointes:


367. Michaud V, Cicali B, Verzicco J, Knowlton CH, Turgeon J. **Yearly medical expenditure in patients treated with CYP2D6-dependent opioids and impact of concomitant treatment with CYP2D6 substrate or inhibitor drugs.** American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-032.

368. Cicali B, Verzicco J, Knowlton CH, Turgeon J, Michaud V. **Increased risk medication related problems due to concomitant administration of CYP2D6-dependent opioids and CYP2D6 interacting drugs.** American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-095.


